Bayesian sample size determination in non-sequential clinical trials: Statistical aspects and some regulatory considerations
- 8 June 2007
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 26 (27), 4914-4924
- https://doi.org/10.1002/sim.2958
Abstract
The most common Bayesian methods for sample size determination (SSD) are reviewed in the non-sequential context of a confirmatory phase III trial in drug development. After recalling the regulatory viewpoint on SSD, we discuss the relevance of the various priors applied to the planning of clinical trials. We then investigate whether these Bayesian methods could compete with the usual frequentist approach to SSD and be considered as acceptable from a regulatory viewpoint. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 19 references indexed in Scilit:
- Subgroup Analyses in Randomized Clinical Trials: Statistical and Regulatory IssuesJournal of Biopharmaceutical Statistics, 2005
- Mid‐course sample size modification in clinical trials based on the observed treatment effectStatistics in Medicine, 2003
- How Large Should a Clinical Trial Be?Journal of the Royal Statistical Society: Series D (The Statistician), 2000
- Two useful distributions for Bayesian predictive procedures under normal modelsJournal of Statistical Planning and Inference, 1999
- Interval-based versus decision theoretic criteria for the choice of sample sizeJournal of the Royal Statistical Society: Series D (The Statistician), 1997
- The choice of sample sizeJournal of the Royal Statistical Society: Series D (The Statistician), 1997
- Sample size determination: a reviewJournal of the Royal Statistical Society: Series D (The Statistician), 1997
- Bayesian sample size determination for normal means and differences between normal meansJournal of the Royal Statistical Society: Series D (The Statistician), 1997
- The choice of sample size-a reply to the discussionJournal of the Royal Statistical Society: Series D (The Statistician), 1997
- An economic approach to clinical trial design and research priority-settingHealth Economics, 1996